Caris Life Sciences, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +24.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.01 | $0.00 | +100.0% | Beat | |
| Q1 FY26 | $-0.02 | $0.00 | +100.0% | Beat | |
| Q4 FY25 | not reported | $0.28 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $0.08 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.54 | not reported | not reported | |
| Q3 FY21 | $1.89 | $2.79 | +47.6% | Beat | |
| Q2 FY21 | $1.74 | $2.04 | +17.2% | Beat | |
| Q1 FY21 | $1.66 | $1.85 | +11.4% | Beat | |
| Q4 FY20 | $1.11 | $1.76 | +58.6% | Beat | |
| Q3 FY20 | $0.85 | $1.04 | +22.4% | Beat | |
| Q2 FY20 | $0.52 | $0.78 | +50.0% | Beat | |
| Q1 FY20 | $0.47 | $0.67 | +42.5% | Beat |
Back to CAI overview · CAI holders · CAI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.